Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development

被引：0

作者：

Chun-Meng Jiang ^{[1
]}

Chun-Wen Pu ^{[2
]}

Ya-Hui Hou ^{[1
]}

Zhe Chen ^{[3
]}

Mohammed Alanazy ^{[4
]}

Lionel Hebbard ^{[4
]}

机构：

[1] Department of Digestive System, the Second Affiliated Hospital of Dalian Medical University

[2] Department of Liver Disease, Dalian the Sixth People’s Hospital

[3] Department of General Surgery, the Second Affiliated Hospital of Dalian Medical University

[4] Storr Liver Unit, Westmead Millennium Institute, University of Sydney

来源：

World Journal of Gastroenterology | 2014年 / 20卷 / 44期

关键词：

Nonalcoholic steatohepatitis; Hepatocellular carcinoma; Inflammation; Microbiome; Bile acids;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma(HCC) is increasing in prevalence and is one of the most common cancers in the world. Chief amongst the risks of attaining HCC are hepatitis B and C infection, aflatoxin B1 ingestion, alcoholism and obesity. The later has been shown to promote non alcoholic fatty liver disease, which can lead to the inflammatory form non alcoholic steatohepatitis(NASH). NASH is a complex metabolic disorder that can impact greatly on hepatic function. The mechanisms by which NASH promotes HCC are only beginning to be characterized. Here in this review, we give an overview of the recent novel mechanisms published that have been associated with NASH and subsequent HCC progression. We will focus our discussion on inflammation and gut derived inflammation and how they contribute to NASH driven HCC.

引用

页码：16464 / 16473

页数：10

共 47 条

[1] Inflammation-and stress-related signaling pathways in hepatocarcinogenesis[J]. Hayato Nakagawa,Shin Maeda.World Journal of Gastroenterology. 2012(31)
[2] Obesity-associated mechanisms of hepatocarcinogenesis[J] . Raffi Karagozian,Zoltán Derdák,Gy?rgy Baffy.Metabolism . 2014
[3] The Receptor TGR5 Protects the Liver From Bile Acid Overload During Liver Regeneration in Mice
Pean, Noemie
Doignon, Isabelle
Garcin, Isabelle
Besnard, Aurore
Julien, Boris
Liu, Bingkai
Branchereau, Sophie
Spraul, Anne
Guettier, Catherine
Humbert, Lydie
Schoonjans, Kristina
Rainteau, Dominique
Tordjmann, Thierry
[J]. HEPATOLOGY, 2013, 58 (04) : 1451 - 1460
[4] Cirrhosis, bile acids and gut microbiota[J] . Jason M Ridlon,Joao Marcelo Alves,Phillip B Hylemon,Jasmohan S Bajaj.Gut Microbes . 2013 (5)
[5] Intestinal Microbiota in Patients With Nonalcoholic Fatty Liver Disease
Mouzaki, Marialena
Comelli, Elena M.
Arendt, Bianca M.
Bonengel, Julia
Fung, Scott K.
Fischer, Sandra E.
McGilvray, Ian D.
Allard, Johane P.
[J]. HEPATOLOGY, 2013, 58 (01) : 120 - 127
[6] Obesity, Insulin Resistance, NASH and Hepatocellular Carcinoma[J] . Jun Yu,Jiayun Shen,Ting Ting Sun,Xiang Zhang,Nathalie Wong.Seminars in Cancer Biology . 2013
[7] Multifaceted roles of Adiponectin in cancer[J] . Lionel Hebbard,Barbara Ranscht.Best Practice ＆ Research Clinical Endocrinology ＆ Metabolism . 2013
[8] Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause?[J] . David van der Poorten,Caroline F. Samer,Mehdi Ramezani‐Moghadam,Sally Coulter,Marina Kacevska,Dennis Schrijnders,Lindsay E. Wu,Duncan McLeod,Elisabetta Bugianesi,Mina Komuta,Tania Roskams,Christopher Liddle,Lionel Hebbard,Jacob George.Hepatology . 2013 (6)
[9] Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease[J] . Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi I. Sciacca,Paul Clopton,Erin Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro.Gastroenterology . 2013
[10] Characterization of gut microbiomes in nonalcoholic steatohepatitis （NASH） patients: A connection between endogenous alcohol and NASH[J] . Lixin Zhu,Susan S. Baker,Chelsea Gill,Wensheng Liu,Razan Alkhouri,Robert D. Baker,Steven R. Gill.Hepatology . 2013 (2)

← 1 2 3 4 5 →